Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 4/20 | 0.38 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.35 |
| ▸ | METAP2 | P50579 | 5/20 | 0.34 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.34 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.32 |
| ▸ | DRD4 | P21917 | 1/20 | 0.32 |
| ▸ | DRD3 | P35462 | 1/20 | 0.32 |
| ▸ | ACLY | P53396 | 1/20 | 0.32 |
| ▸ | SPR | P35270 | 2/20 | 0.32 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.31 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.31 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.31 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2531711 | 0.88 | DRD2 (0.43) | DRD2FFAR4METAP2S1PR2DRD4 | |
| SCHEMBL3384895 | 0.85 | DRD2 (0.47) | DRD2FFAR4METAP2S1PR2GRIN2B | |
| SCHEMBL1331572 | 0.79 | STS (0.39) | — | |
| SCHEMBL3346703 | 0.78 | DRD2 (0.36) | DRD2FFAR4METAP2S1PR2DRD4 | |
| SCHEMBL3346698 | 0.78 | DRD2 (0.36) | DRD2FFAR4METAP2S1PR2DRD4 | |
| SCHEMBL15689692 | 0.76 | OPRM1 (0.49) | GRIN2B | |
| SCHEMBL2535627 | 0.76 | S1PR2 (0.39) | DRD2S1PR2DRD4DRD3SPR | |
| SCHEMBL3125858 | 0.76 | DRD2 (0.41) | DRD2DRD4DRD3SPR | |
| SCHEMBL1331319 | 0.75 | DRD2 (0.38) | DRD2METAP2DRD4DRD3 | |
| SCHEMBL2463684 | 0.75 | DRD2 (0.36) | DRD2METAP2S1PR2DRD3ACLY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2367785-B1 | NOVEL 3-PHENYL-AZETIDINE DERIVATIVES USEFUL AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION | INTEGRATIVE RES LAB SWEDEN AB (SE) | 2014-10-15 | — | — | EP | disclosed |
| EP-2367786-B1 | NOVEL 1 -ALKYL- 3 -HYDROXY- 3 -PHENYLAZETIDINE DERIVATIVES USEFUL AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION | NSAB AF NEUROSEARCH SWEDEN AB (DK) | 2013-01-09 | — | — | EP | disclosed |
| US-20110257148-A1 | NOVEL 1-ALKYL-3-HYDROXY-3-PHENYLAZETIDINE DERIVATIVES USEFUL AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2011-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257148-A1 | NOVEL 1-ALKYL-3-HYDROXY-3-PHENYLAZETIDINE DERIVATIVES USEFUL AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION | DBH, SLC6A3, ADRA2B | DRD2 7/4885FFAR4 1965/4885METAP2 3260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.